- Home
- KIDS vs OMER Comparison
KIDS vs OMER Comparison
Compare KIDS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- OMER
- Stock Information
- Founded
- KIDS 2007
- OMER 1994
- Country
- KIDS United States
- OMER United States
- Employees
- KIDS N/A
- OMER N/A
- Industry
- KIDS Medical/Dental Instruments
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- KIDS Health Care
- OMER Health Care
- Exchange
- KIDS Nasdaq
- OMER Nasdaq
- Market Cap
- KIDS 601.5M
- OMER 530.2M
- IPO Year
- KIDS 2017
- OMER 2009
- Fundamental
- Price
- KIDS $24.26
- OMER $9.13
- Analyst Decision
- KIDS Buy
- OMER Buy
- Analyst Count
- KIDS 6
- OMER 4
- Target Price
- KIDS $37.67
- OMER $22.50
- AVG Volume (30 Days)
- KIDS 317.8K
- OMER 509.4K
- Earning Date
- KIDS 03-05-2025
- OMER 03-31-2025
- Dividend Yield
- KIDS N/A
- OMER N/A
- EPS Growth
- KIDS N/A
- OMER N/A
- EPS
- KIDS N/A
- OMER N/A
- Revenue
- KIDS $189,673,000.00
- OMER N/A
- Revenue This Year
- KIDS $39.26
- OMER N/A
- Revenue Next Year
- KIDS $18.08
- OMER N/A
- P/E Ratio
- KIDS N/A
- OMER N/A
- Revenue Growth
- KIDS 33.47
- OMER N/A
- 52 Week Low
- KIDS $21.02
- OMER $2.61
- 52 Week High
- KIDS $35.99
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- KIDS 45.67
- OMER 50.45
- Support Level
- KIDS $23.55
- OMER $8.28
- Resistance Level
- KIDS $25.45
- OMER $9.08
- Average True Range (ATR)
- KIDS 1.26
- OMER 0.58
- MACD
- KIDS -0.28
- OMER -0.05
- Stochastic Oscillator
- KIDS 20.48
- OMER 62.58
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.